The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.
An analysis of EvaluatePharma data shows that, in a Bristol-Myers Squelgene world, all big pharmas are increasing their reliance on external projects.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
Up-front fees paid out by biopharma companies to seal licensing deals noticeably dipped in the second quarter of the year – then Gilead and Galapagos came along.
For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.